Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody–drug conjugate (ADC) directed against Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer.1,2

Nonclinical data suggest the anticancer activity of enfortumab vedotin is due to binding to Nectin-4–expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell. This is believed to prevent cell reproduction (cell cycle arrest) and to cause programmed cell death (apoptosis).1

Enfortumab vedotin is being developed in collaboration with Astellas.

Proposed mechanism of action

View Details
Seagen medication enfortumab vedotin
Seagen medication enfortumab vedotin annotated

Enfortumab vedotin is an investigational agent in this setting. Its safety and efficacy have not yet been established.


  1. PADCEV Prescribing Information. Northbrook, IL: Astellas, Inc. December 2019.
  2. Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003-3013.